QIAN Stock Chart & Stats
$912.70
$0.00(0.00%)
At close: 4:00 PM EDT
$912.70
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$737.61 - $960.74
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$193.86B
Enterprise Value$8.98B
Total Cash (Recent Filing)$793.50M
Total Debt (Recent Filing)$1.64B
Price to Earnings (P/E)25.8
Beta0.04
Next Earnings
Nov 04, 2026EPS Estimate
11.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.95
Shares Outstanding206,074,750
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.61
Price to Sales (P/S)4.71
P/FCF Ratio21.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$915.05Price Target Upside0.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)45.53
Revenue Forecast (FY)$39.88B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelRecurring consumables and assay replenishment create repeat demand as customers continue testing and research. Instruments and automation can also increase pull-through of compatible reagents, supporting customer retention and a more durable revenue base than one-time equipment sales alone.
Strong Profitability And Cash GenerationHealthy margins and substantial operating and free cash flow provide resources for research, product launches, dividends and other capital allocation. Manageable leverage further supports resilience, allowing Qiagen to fund its business while retaining flexibility through changing demand conditions.
Growth Pillars And Product PipelineOutperformance in Sample Technologies, QIAcuity and digital insights indicates that growth is not dependent on a single product category. New connected systems, QIAmini, Parse advances and expanded diagnostic menus could broaden adoption and support growth over coming quarters.
Bears Say
Takeover Execution UncertaintyThe proposed take-private transaction creates a material execution and governance overhang until approvals, tender conditions and closing requirements are resolved. Potential disruption, board changes, delisting steps and altered ownership priorities could affect employees, partners and business planning during the next several months.
Weakness In Key Categories And RegionsDeclines across QIAstat, PCR and nucleic-acid amplification expose pressure in important parts of the portfolio, while China and EMEA weakness limits geographic support. Recovery therefore depends on growth pillars and new launches offsetting softness in established categories and markets.
Uneven Growth And Cash ConversionThe rebound in recent profitability is encouraging, but the uneven multiyear trajectory shows that earnings and cash realization can be sensitive to demand and operating conditions. This variability makes sustained margin expansion less certain and can constrain confidence in predictable compounding.
Qiagen News
QIAN FAQ
What was Qiagen NV’s price range in the past 12 months?
Qiagen NV lowest stock price was $737.61 and its highest was $960.74 in the past 12 months.
What is Qiagen NV’s market cap?
Qiagen NV’s market cap is $193.86B.
When is Qiagen NV’s upcoming earnings report date?
Qiagen NV’s upcoming earnings report date is Nov 04, 2026 which is in 10 days.
How were Qiagen NV’s earnings last quarter?
Qiagen NV released its earnings results on Aug 05, 2026. The company reported $11.575 earnings per share for the quarter, beating the consensus estimate of $11.164 by $0.411.
Is Qiagen NV overvalued?
According to Wall Street analysts Qiagen NV’s price is currently Undervalued.
Does Qiagen NV pay dividends?
Qiagen NV does not currently pay dividends.
What is Qiagen NV’s EPS estimate?
Qiagen NV’s EPS estimate is 11.71.
How many shares outstanding does Qiagen NV have?
Qiagen NV has 206,074,750 shares outstanding.
What happened to Qiagen NV’s price movement after its last earnings report?
Qiagen NV reported an EPS of $11.575 in its last earnings report, beating expectations of $11.164. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Qiagen NV?
Currently, no hedge funds are holding shares in MX:QIAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Qiagen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$915.05 (0.26% Upside)
$915.05 (0.26% Upside)
Blogger Sentiment
Bearish
MX:QIAN Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth $426.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.85%
12-Months-Change
Fundamentals
Return on Equity
11.60%
Trailing 12-Months
Asset Growth
1.12%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
QIAN Company Deck
QIAN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: management reported results above outlook for sales and adjusted EPS, strong cash generation, high profitability, and clear momentum in key growth pillars (Sample Technologies, QIAcuity, QDI) alongside active product launches and capital returns (40% dividend increase, $500M repurchase). Challenges include declines in QIAstat and PCR product groups, China and regional softness, a notable revenue loss from reduced immigration testing (~$35M) affecting QuantiFERON comparisons, modest margin and inventory pressures, and ongoing strategic/leadership transition that creates near-term uncertainty. On balance, the company emphasized confidence in a stronger second half of 2026 driven by new product rollouts and easing comparables.View all MX:QIAN earnings summariesQIAN Stock 12 Month Forecast
Average Price Target
$915.05
▲(0.26% Upside)